Progress in PDE4 targeted therapy for inflammatory diseases / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 353-358, 2014.
Artigo
em Chinês
| WPRIM
| ID: wpr-251696
ABSTRACT
cAMP-specific phosphodiesterase type 4 (PDE4) is one of the hot targets for treatment of inflammatory diseases. PDE4 inhibitors can suppress inflammation by increasing the concentration of cAMP in inflammatory cells. The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmacologia
/
Artrite
/
Asma
/
Sulfonas
/
Talidomida
/
Tiazóis
/
Benzamidas
/
Doenças Inflamatórias Intestinais
/
Ciclopropanos
/
Doença Pulmonar Obstrutiva Crônica
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Zhejiang University. Medical sciences
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS